Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

To learn if giving tivozanib in combination with nivolumab can help to control advanced nccRCC.

Trial Details

NCT ID
NCT06053658
Phase
PHASE2
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Tivozanib
  • Nivolumab
Locations (sample)
  • Irvine, California, United States|33.66946,-117.82311
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Patients with histologically or cytologically confirmed metastatic non-clear cell renal cell carcinoma of papillary, chromophobe, oncocytic neoplas…
  • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  • Up to 1 systemic line of therapy (either monotherapy or combination) including prior immunotherapy (anti-PD1, PD-L1, or CTLA-4) and multi-tyrosine …
  • Age ≥18 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →